
==== Front
Eur J Pediatr
Eur J Pediatr
European Journal of Pediatrics
0340-6199
1432-1076
Springer Berlin Heidelberg Berlin/Heidelberg

39112805
5716
10.1007/s00431-024-05716-y
Research
The Impact of Different MEFV Genotypes on Clinical Phenotype of Patients with Familial Mediterranean Fever: Special Emphasis on Joint Involvement
http://orcid.org/0000-0002-7554-3320
Aslan Esma
http://orcid.org/0000-0001-6102-4055
Akay Nergis
http://orcid.org/0000-0002-1282-8273
Gul Umit
http://orcid.org/0000-0002-8174-5308
Konte Elif Kilic
http://orcid.org/0000-0003-0137-0460
Gunalp Aybuke
http://orcid.org/0000-0002-6963-9668
Haslak Fatih
http://orcid.org/0000-0002-2400-6955
Adrovic Amra
http://orcid.org/0000-0001-8459-2872
Barut Kenan
http://orcid.org/0000-0002-7834-4909
Yildiz Mehmet
http://orcid.org/0000-0002-5365-3457
Sahin Sezgin
http://orcid.org/0000-0002-1125-7720
Kasapcopur Ozgur ozgurkasapcopur@hotmail.com

grid.506076.2 0000 0004 1797 5496 Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Türkiye
Communicated by Peter de Winter

7 8 2024
7 8 2024
2024
183 10 44034410
22 6 2024
23 7 2024
5 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease worldwide. In this retrospective cohort study, we aimed to assess the effects of various MEFV genotypes on the clinical characteristics of the patients, with a special focus on the joint involvement. In total, 782 patients with FMF were categorized into 3 groups according to the MEFV mutation; Group 1: Patients homozygous for M694V; Group 2: Patients carrying other pathogenic MEFV variants in exon 10 in homozygous or compound heterozygous states; and Group 3: FMF patients with other variants or without mutations. Clinical and demographic findings were compared between groups. Among the 782 FMF patients, total frequency of arthritis was 237 (30.3%): 207 (26.4%) were acute monoarthritis and 67 (8.5%) were chronic arthritis. Both the frequency of arthritis (acute and/or chronic) (40.4% vs. 24.8% vs. 26.7%; p:0.001) and acute monoarthritis (35.4% vs. 20% vs. 23.7%; p:0.001) were significantly higher in Group 1 than in the other groups. FMF patients with chronic arthritis showed a distinct juvenile idiopathic arthritis (JIA) distribution pattern with a more frequent enthesitis-related arthritis (ERA) subtype (43.2%). HLA-B27 was positive in 24% of the ERA patients.

Conclusion: Homozygous M694V mutation is associated with a more frequent and longer acute monoarthritis comparing to other MEFV genotypes. In addition, the risk of chronic arthritis seems not related to the MEFV mutations. However, FMF patients with chronic arthritis show a distinct ILAR JIA distribution pattern with a more frequent ERA and undifferentiated arthritis subtype.

What is known:	
• Homozygous M694V mutation is associated with a more frequent and longer acute monoarthritis	
What is new:	
• FMF patients with chronic arthritis show a distinct ILAR JIA distribution pattern with a more frequent ERA subtype	
• ERA patients with negative HLA-B27 antigen should also be assessed for polyserositis episodes of FMF, especially in countries with high FMF carrier frequency	

Keywords

Arthritis
Familial Mediterranean fever
Genotypes
HLA-B27
Enthesitis-related arthritis
Istanbul University CerrahpaşaOpen access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK).

issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease worldwide [1]. It has a strong ethnic distribution in Mediterranean and Middle Eastern societies, such as Turks, Armenians, Jews, and Arabs [2]. It is characterized by fever and self-limiting attacks of polyserositis that occur at irregular intervals, usually lasting 12 to 72 h [3]. The MEFV (Mediterranean fever) gene, the causative gene of the disease, is located on the short arm of chromosome 16 and consists of 10 exons [4]. More than 350 sequence analyses associated with FMF have been identified in the MEFV gene. Although pathogenic or likely pathogenic variants are mostly located in exon 10, many other mutations in exons 2, 3, and 5 are also associated with FMF [5–7]. The type of mutations in MEFV gene impact clinical findings and disease phenotype [8, 9].

Familial Mediterranean fever is characterized by inflammatory attacks lasting between 6 and 72 h. During these inflammatory episodes, fever, generalized abdominal pain, chest pain, erysipelas-like rash are characteristic findings of the disease. Joint involvement is one of the common and important findings of FMF and can sometimes be the first sign of the disease in children [5, 8, 10]. The prevalence of arthritis among individuals with FMF varies across different ethnic groups. It appears that the prevalence is lower in Arabs, Turks, and Armenians when compared to Jews [11] [12]. Patients with FMF typically experience temporary monoarthritis affecting the large joints of their lower extremities. This condition usually lasts for 7 to 10 days, which is longer than other symptoms. It is important to note that the arthritis seen in FMF is generally non-erosive and does not lead to long-term sequale. However, in rare cases, up to 2–5% of patients may develop chronic arthritis in the hips or knees [5]. Additionally, there are increasing number of cases where sacroiliitis accompanies FMF in the literature [13].

The primary goal of this retrospective cohort study was to evaluate the clinical features of patients, identify the prevalence and characteristics of arthritis in children with FMF, and investigate the influence of MEFV gene variants on their clinical features in a substantial pediatric FMF population.

Material and methods

Study population and definitions

The present retrospective cohort study enrolled patients who had been diagnosed with FMF before the age of 18, Istanbul Unıversity-Cerrahpasa Department of paediatric rheumatology between September 2022 and May 2023. The inclusion criteria were that the patients met the Turkish paediatric FMF criteria, had a follow-up period of at least 6 months, and the patient/legal representative agreed to participate in the study. The Turkish paediatric FMF criteria set includes the following items: fever (at least three attacks, lasting 6–72 h), abdominal pain (at least three attacks, lasting 6–72 h), chest pain (at least three attacks, lasting 6–72 h), arthritis (at least three attacks lasting 6–72 h, oligoarthritis) and family history. At least two of these five criteria must be present for the diagnosis of FMF [7]. Patients who did not meet the Turkish pediatric FMF criteria, patients with a follow-up period of less than 6 months, patients with fundamental deficiencies in disease-related data, and patients who did not volunteer to participate in the study were excluded from the study. The study was initially planned to include 850 patients. However, seventeen patients did not meet the Turkish criteria for pediatric FMF, forty-three patients had a follow-up period of less than six months, seven patients had essential deficiencies in disease-related data, and one patient did not volunteer to participate in the study; therefore, they were excluded. Consequently, a total of 782 patients were included in the study. Demographic, clinical, genetic, and laboratory data of the patients were obtained from the patient records and these data were confirmed by the patients/parents during the outpatient clinic examination.

Patients with arthritis were allocated into two categories: those with acute monoarthritis and those with chronic arthritis. Chronic arthritis was defined as any arthritic condition that persisted for more than six weeks. Patients diagnosed with chronic arthritis and meeting the International Association of Rheumatology Associations (ILAR) classification criteria were subsequently categorized into one of seven subtypes of Juvenile Idiopathic Arthritis (JIA) according to the ILAR definitions: systemic JIA, oligo articular JIA, rheumatoid factor positive polyarticular JIA, rheumatoid factor negative polyarticular JIA, enthesitis-related arthritis (ERA), psoriatic arthritis, and undifferentiated JIA [14].

Colchicine resistance is defined as having at least one attack per month over the last 3 months despite the highest tolerated dose in patients who have good colchicine compliance [15]. According to recommendations, the standard colchicine dose is 1.2 mg/m2/day. The colchicine dose for children under 5 years of age is 0.5 mg/day; 0.5–1 mg/day for children between the ages of 5 and 10, and 1.5 mg/day for children older than 10 [16]. In case of colchicine resistance, colchicine is first increased to the highest tolerated dose. If the attacks are not controlled, a different brand of colchicine is tried. Anti- interleukin-1 (IL-1) treatment is approved in patients whose attacks continue despite all these interventions.

Genetic analysis of MEFV gene

All patients were analysed for sequence variants in exons 2, 3, 5, and 10 of the MEFV gene. DNA isolation from blood samples was performed according to standard procedures. The test uses polymerase chain reaction (PCR) and reverse hybridization (FMF StripAssay, ViennaLab). The study group was divided into 3 groups according to the pathogenicity of MEFV mutation. Group 1: Patients homozygous for M694V; Group 2: Patients carrying other pathogenic MEFV variants (M694I, M680I, V726A) in exon 10 in homozygous or compound heterozygous states; and Group 3: FMF patients with other variants (whether homozygous or heterozygous) or without mutations. All these 3 groups were compared in terms of demographic data, clinical features, and joint involvement [2, 17].

Ethical approval

The Istanbul University-Cerrahpasa Institutional Review Board approved this study. The approval date and protocol number are 07.12.2022–558367. Written informed consent was received from the legal representatives of patients. The study was performed according to the principles of the Declaration of Helsinki.

Statistical analysis

Statistical analyses were performed using the IBM SPSS 20.0 program. The Kolmogorov–Smirnov test was used to analyse the distributions of variables. Continuous variables with a normal distribution are given as mean ± standard deviation (SD), and those that do not follow a normal distribution are given as median (minimum–maximum). The chi-square test was applied to compare categorical variables in patients categorized according to the MEFV genotype. For continuous variables that were not normally distributed, the Kruskal–Wallis test was used. Statistical significance is defined as p-value < 0.05.

Results

Demographic and clinical features

A total of 782 FMF patients were included in the study. Three hundred eighty-four of them (49.1%) were female. The average age of the patients at the time of the study was 14.2 ± 4.4 years. The median age ​​of disease onset and diagnosis were 3 (0–16) years and 6 (1–17) years, respectively. Abdominal pain (82.9%), fever (79.2%), and arthralgia (63.4%) were the most frequently reported symptoms by patients. Acute monoarthritis was the fourth most common manifestation, which was observed in 207 (26.5%) patients. All patients received colchicine treatment. Of the 52 (6.6%) patients who had colchicine resistance, 47 (6%) patients were on IL-1 inhibitors and 5 (0.6%) patients were in the process of getting approval from the health authorities. Consanguineous marriage was observed in 219 (28%) patients. Two (0.25%) patients had renal amyloidosis (Table 1). Table 1 Demographic data, symptoms and clinical presentations of patients in our cohort study

	n (%) or
mean ± SD or median (min -max)	
Total number of patients	782	
Gender (female)	384 (49.1%)	
Age at last visits (years)	14.2 ± 4.4	
Age of symptom onset (years)	3 (0–16)	
Age of disease diagnosis (years)	6 (1–17)	
Fever	619 (79.2%)	
Abdominal pain	648 (82.9%)	
Chest pain	164 (21%)	
Arthritis	237 (30.3%)	
 -Acute monoarthritis	207 (26.5%)	
 -Chronic Arthritis	67 (8.5%)	
Arthralgia	496 (63.4%)	
Erysipelas-like erythema	30 (3.8%)	
Prolonged febrile myalgia	8 (1%)	
Renal amyloidosis	2 (0.2%)	
Colchicine resistance	52 (6.6%)	
The dose of colchicine (mg/day)	1.47 ± 0.6	
Biological agent requirement

Canakinumab

Adalimumab

Etanercept

Anakinra

Tocilizumab

Certolizumab

	91 (11.6%)

40 (5.1%)

27 (3.4%)

15 (1.9%)

7 (0.9%)

1 (0.1%)

1 (0.1%)

	
SD standart deviation min. minimum, max. maximum

One hundred eighty-four of our patients (23.5%) had at least one comorbid disease. The most common comorbid disease was JIA (n = 67, 8.5%), followed by periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome (n = 17, 2.1%), allergic asthma (n = 14, 1.8%) and immunoglobin A (IgA) vasculitis (n = 8, 1%). Among FMF patients with comorbid disease, 43 patients (23.4%) anti-tumour necrosis factor (TNF) therapy, 36 patients (19.5%) methotrexate, 3 patients (1.6%) azathioprine, 2 patients (1.0%) mycophenolate mofetil, and 2 patients (1.0%) anti-interleukin 6 (IL-6) treatment.

MEFV gene variants of the study population

The Mediterranean fever gene variant distribution in our study was as follows: M694V allele in 518 (66.2%) patients, R202Q allele in 195 (24.9%), M680I allele in 111 (14.2%), V726A allele in 87 (11.1%) and E148Q allele in 71 (9%) patients. The most common MEFV genotype was M694V homozygous mutation (n = 223, 28.5%), followed by M694V heterozygous mutation (n = 124, 15.8%). No mutation was detected in 55 (7%) patients (Table 2). Among 184 patients with comorbidities, the most common genotype was M694V homozygous mutation (12%), and the most common allele was M694V allele (15%). Table 2 Distribution of different MEFV variants in the entire study group

Mutations	n (%)	
M694V Homozygous

M694V Heterozygous

R202Q Homozygous

R202Q Heterozygous

M694V/M680I Compound Heterozygous

M694V/R202Q Compound Heterozygous

M694V/V726A Compound Heterozygous

E148Q Heterozygous

V726A Heterozygous

M680I Heterozygous

M680I Homozygous

M694V/E148Q Compound Heterozygous

M694V/R761H Compound Heterozygous

No variant detected

Others

	223 (%28.5)

124 (%15.8)

81 (%10.3)

64 (%8.1)

54 (%6.9)

44 (%5.6)

40 (%5.1)

40 (%5.1)

28 (%3.5)

24 (%3)

19 (%2.4)

17 (%2.1)

12 (%1.5)

55 (%7)

82 (%10.4)

	

Comparisons according to the genotypes of the patients

Based on genotypes of the patients; study cohort were divided into 3 groups: Patients homozygous for M694V (Group 1), patients carrying other pathogenic MEFV variants (M694I, M680I, V726A) in exon 10 either in a homozygous or compound heterozygous state (Group 2) and FMF patients with other variants (homozygous, heterozygous or compound heterozygous) or without any mutation (Group 3). There were 223 patients in Group 1, 125 in Group 2, and 434 in Group 3. The age at disease onset (2 years vs. 3 years vs. 4 years; p < 0.001) and the age at diagnosis (4 years vs. 5 years vs. 6 years; p < 0.001) in Group 1 were earlier than the other groups. The frequency of arthritis (35.4% vs. 20% vs. 23.7%; p:0.001) and erysipelas-like erythema (ELE) (8.5% vs. 2.4% vs. 1.8%; p < 0.001) were also significantly higher in Group 1 than in the other groups. Chest pain in Group 2 (31.2%) was more pronounced comparing to Group 1 (25.6%) and Group 3 (15.7%) (p < 0.001). The average number of FMF episodes in the last 6 months (1 vs. 0 vs. 0; p < 0.001) was higher in Group 1 than in the other groups. The mean colchicine dose in all study cohort was 1.47 ± 0.6 mg/day. Additionally, the average colchicine dose (1.64 ± 0.5 mg vs. 1.5 ± 0.6 mg vs. 1.38 ± 0.64 mg; p < 0.001), the frequency of colchicine resistance (16.6% vs. 6.4% vs. 1.6%; p < 0.001), the need for a different colchicine brand (8.5% vs. 1.6% vs. 0.9%; p < 0.001) and the use of anti-IL1 therapy (14.3% vs. 6.4% vs. 1.6%; p < 0.001) was higher in Group 1 than in Group 2 and Group 3. No significant difference was detected between the groups in terms of comorbidities, consanguineous marriages, and the presence of chronic arthritis. There were 2 patients with renal amyloidosis; one was harbouring the M694V homozygous (Group 1) mutation and the other patient compound heterozygous M680I/V726A (Group 2) mutation.

Joint involvement

The total frequency of arthritis in our cohort was 237 (30.3%). Of these, 207 (26.4%) were acute monoarthritis and 67 (8.5%) were chronic arthritis. Among the 237 patients with arthritis, 37 developed both acute and chronic arthritis in the course of the disease. Among the patients with chronic arthritis, the most frequent 3 genotypes in descending order were M694V homozygous mutation (n = 22, 32.8%), M694V/M680I compound heterozygous mutation (n = 9, 13.4%) and M694V heterozygous mutation (n = 9, 13.4%). Other less frequent mutations were as follows: M694V/R202Q compound heterozygous in 5 patients (7.5%), M694V/V726A compound heterozygous in 4 patients (5.9%), E148Q heterozygous in 3 patients (4.5%), R202Q heterozygous in two patients (3%), M694V/E148Q compound heterozygous in two patients (3%), M680I/R202Q compound heterozygous in one patient (1.5%), M680I heterozygous in one patient (1.5%), M680I homozygous in one patient (1.5%), M680I/E148Q compound heterozygous in one patient (1.5%), V726A homozygous in one patient (1.5%), V726A/R761H compound heterozygous in one patient (1.5%), V726A heterozygous in two patients (3%), and R202Q homozygous in one patient (1.5%). No mutations were detected in two patients (3%). Additionally, the most common alleles in this group are M694V allele (n = 51, 6.5%), R202Q allele (n = 22, 2.8%), and M680I allele (n = 12, 1.5%), respectively. The distribution of JIA subgroups in patients with chronic arthritis was as follows: enthesitis-related arthritis (ERA) in 29 patients (43.2%), oligoarticular JIA (oJIA) in 13 (19.4%), polyarticular JIA (polyJIA) in 8 (11.9%), systemic JIA (sJIA) in 2 (3%), juvenile psoriatic arthritis (jPsA) in 1 (1.5%), and undifferentiated chronic arthritis in 14 patients (20.9%). Of the 25/29 ERA patients who have been analysed for the presence of HLA-B27 antigen, 24% (n = 6) was positive for HLA-B27 antigen.

All 3 groups were compared in terms of the frequency of arthritis (acute and/or chronic), acute monoarthritis and chronic arthritis. Both the frequency of arthritis (40.4% vs. 24.8% vs. 26.7%; p:0.001) and acute monoarthritis (35.4% vs. 20% vs. 23.7%; p:0.001) were found to be significantly higher in Group 1 than in the other groups. The average duration of acute monoarthritis (2 days vs. 1 day vs. 1 day; p:0.001) was longer in patients with M6964V homozygous mutation. The rate of arthralgia and chronic arthritis did not differ between groups (Table 3). Table 3 Comparison of the characteristics of familial Mediterranean fever-related arthritis according to genotype

	Total
n (%)	Group 1*
n (%)	Group 2*
n (%)	Group 3*
n (%)	p value	
Patients	782 (100%)	223 (100%)	125 (100%)	434 (100%)		
Patients with arthritis	237 (30.3%)	91 (40.8%)	31 (24.8%)	115 (26.5%)	p = 0.001	
 Acute monoarthritis	207 (26.5%)	79 (35.4%)	25 (20%)	103 (23.7%)	p = 0.001	
 Chronic Arthritis	67 (8.5%)	22 (9.8%)	14 (11.2%)	31 (7.1%)	0.35	
   ERA	29 (43.2%)	12 (54.5%)	3 (20%)	14 (46.7%)	0.27	
   oJIA	13 (19.4%)	4 (18.2%)	3 (20%)	6 (20%)	0.72	
  PolyJIA	8 (11.9%)	1 (4.5%)	4 (26.7%)	3 (10%)	p< 0.05	
   sJIA	2 (3%)	1 (4.5%)	-	1 (3.3%)	0.72	
   JPsA	1 (1.5%)	-	-	1 (3.3%)	0.67	
   uJIA	14 (20.9%)	4 (18.2%)	4 (26.7%)	6 (20%)	0.40	
Acute monoarthritis attack duration

(day) (median, min–max)

	2 (0–30)	2 (0–30)	1 (0–7)	1 (0–14)	p < 0.05	
ERA enthesitis-related arthritis, oJIA oligoarticular juvenile idiopathic arthritis, PolyJIA polyarticular juvenile idiopathic arthritis, sJIA systemic juvenile idiopathic arthritis, JPsA juvenile psoriatic arthritis, uJIA undifferentiated JIA, SD standart deviation min. minimum, max. maximum

*Group 1: Patients homozygous for M694V Group 2: patients carrying other pathogenic MEFV variants (M694I, M680I, V726A) in exon 10 either in a homozygous or compound heterozygous state Group 3: Patients with other variants (homozygous, heterozygous or compound heterozygous) or without any mutation

Discussion

Our study investigated the impact of genotype on the demographic and clinical characteristics in a large paediatric FMF cohort. In addition, we aimed to particularly focus on the association of 3 different genotype groups with joint involvement. Familial Mediterranean fever patients homozygous for M694V are likely to develop acute monoarthritis, which also lasts longer comparing to other genotypes.

Arthritis, which is the presenting manifestation in a sort of FMF patients, is not uncommon in FMF [5, 8]. In previously published studies, the frequency of arthritis varies between 18.5% and 43.2%, and the frequency of arthralgia varies between 31% and 63.7% [1, 18–23]. Consistent with these papers, a similar rate of arthritis (26.5%) and arthralgia (63.4%) was observed in our patient cohort.

The presence of the M694V allele, especially the M694V homozygous mutation is closely associated with musculoskeletal manifestations. Besides, several other manifestations including arthritis, arthralgia and exertional leg pain are also more common in M694V homozygous patients [18, 23–26]. Likewise, the frequency of arthritis and acute monoarthritis were higher, and the duration of acute monoarthritis was longer in the M694V homozygous group compared to the other two groups in our cohort. However, there was no difference between genotype groups in the frequency of chronic arthritis.

The frequency of several diseases increases in FMF patients, possibly due to the impaired imbalance between the pro- and anti-inflammatory pathways of the innate immune system [13, 27–30]. Additionally, many studies have reported that the pathogenic alleles in exon 10, especially M694V, increase the frequency of comorbid diseases [27, 28, 31]. Besides, individuals who may also have other susceptibility factors (e.g., FMF) for JIA are at a higher risk of developing chronic arthritis [32]. Data on the long-term outcomes of chronic arthritis in patients with FMF are limited. In a Syrian study, of the 71 FMF patients with arthritis, two patients (3%) developed joint deformity and required hip replacement surgery [25].

In our cohort, among the 184 patients with comorbidities, the most common disease was JIA, with a frequency of 36.4%. However, no significant difference was detected in the frequency of comorbidities between M694V homozygous group and the other groups. The most frequent JIA subtypes in our FMF patients with chronic arthritis were ERA (43.2%), undifferentiated JIA (20.9%) and oJIA (19.4%). In a previous study conducted on the frequency of JIA subgroups in our country, the most common subtypes were oligoarticular JIA (38.8%) and ERA (23.2%), followed by polyarthritis (17.8%), systemic arthritis (12.2%), JPsA (5.2%), and undifferentiated arthritis (2.8%) [33]. Compared to JIA cohort without FMF, our FMF cohort displayed a distinct JIA subtype distribution with a more frequent ERA and undifferentiated arthritis subtypes. Similar to our study, recent studies have also reported that the incidence of ERA has increased in patients with FMF [13, 34, 35]. Higher rates of sacroiliitis, which has been reported as the most frequent chronic joint involvement in FMF patients, may explain the predominance of ERA subtype in our FMF cohort. Besides, our FMF plus ERA patients have exhibited lower rates of HLA-B27 positivity comparing to a previously multicentre JIA study conducted in our country (24.0% vs. 51.7%) [33].

In previous reports, M694V homozygous mutation is associated with a more severe clinical phenotype with an earlier disease onset and lower response to colchicine treatment [28, 36, 37]. Also, in FMF patients with arthritis, the required colchicine dose in the treatment and the rate of colchicine unresponsiveness were higher than the average FMF population [38]. In our study, consistent with the literature, earlier age at disease onset and diagnosis, and higher-doses of colchicine requirement were observed in the M694V homozygous group compared to the other two groups. The treatment algorithm for FMF patients with arthritis should be based on the EULAR recommendations, which propose intra-articular steroid injections and the use of synthetic or biological DMARDs [39].

The most important limitation of our study is its retrospective design and absence of data regarding which joints are affected during the course of the disease. Our strengths are that the MEFV gene analysis was performed in all patients of our cohort, longer follow-up period and detailed assessment of joint involvement patterns.

In conclusion, homozygous M694V mutation is associated with a more frequent and longer acute monoarthritis comparing to other MEFV genotypes. In addition, the risk of chronic arthritis seems not related to the MEFV mutations. However, FMF patients with chronic arthritis show a distinct ILAR JIA distribution pattern with a more frequent ERA and undifferentiated arthritis subtype.

Abbreviations

ELE Erysipelas-like erythema

ERA Eenthesitis-related arthritis

FMF Familial Mediterranean Fever

HLAB-27 Human Leukocyte Antigen B-27

IgA Immunoglobin A

IL Interleukin

ILAR International Association of Rheumatology Associations

JIA Juvenile Idiopathic Arthritis

JPsA Juvenile psoriatic arthritis

Max Maximum

MEFV Mediterranean fever

Min Minimum

oJIA Oligoarticular JIA

PCR Polymerase chain reaction

PFAPA Periodic fever, aphthous stomatitis, pharyngitis and adenitis

PolyJIA Polyarticular JIA

SD Standard deviation

sJIA Systemic JIA

TNF Tumour necrosis factor

Acknowledgements

None.

Author contributions

Concept – Ozgur Kasapcopur, Esma Aslan, Sezgin Sahin; Design - Ozgur Kasapcopur, Esma Aslan, Sezgin Sahin; Supervision – Amra Adrovic, Sezgin Sahin, Kenan Barut, Mehmet Yıldız; Data Collection and/or Processing – Esma Aslan, Mehmet Yıldız, Elif Konte Kılıç, Umit Gül, Nergis Akay, Aybüke Gunalp, Fatih Haslak; Analysis and/or Interpretation; Esma Aslan, Sezgin Sahin, Mehmet Yıldız Literature Search - Esma Aslan, Mehmet Yıldız, Elif Konte Kılıç, Umit Gül, Nergis Akay, Aybüke Gunalp, Fatih Haslak; Writing Manuscript – Esma Aslan, Sezgin Sahin, Mehmet Yıldız; Critical Review – Sezgin Sahin, Mehmet Yıldız, Kenan Barut, Özgür Kasapcopur.

Funding

Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK). The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Informed consent

Written informed consent was obtained from all the participants in this study, and no identifying information of any participant was included in this paper.

Conflict of interest

The authors declare no competing interests.

The patient and public involvement statement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Data sharing statement

All data relevant to the study are included in the article.

Previous presentation

The data from this study were presented as an oral presentation at the Pediatric Rheumatology European Society (PReS) Congress-the Young Investigators Meeting; on September 28 2023, in Rotterdam, Netherlands (Abstract; ABS-1774).

Prepublication note

None.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Barut K Familial Mediterranean fever in childhood: a single-center experience Rheumatol Int 2018 38 1 67 74 10.1007/s00296-017-3796-0 28828621
Barut K et al (2018) Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int 38(1):67–7428828621
2. Alghamdi M Familial Mediterranean fever, review of the literature Clin Rheumatol 2017 36 8 1707 1713 10.1007/s10067-017-3715-5 28624931
Alghamdi M (2017) Familial Mediterranean fever, review of the literature. Clin Rheumatol 36(8):1707–171328624931
3. Özen S Batu ED Demir S Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management Front Immunol 2017 8 253 10.3389/fimmu.2017.00253 28386255
Özen S, Batu ED, Demir S (2017) Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management. Front Immunol 8:25328386255
4. Padeh S Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever J Rheumatol 2003 30 1 185 190 12508410
Padeh S et al (2003) Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol 30(1):185–19012508410
5. Yıldız M Haşlak F Adrovic A Barut K Kasapçopur Ö Autoinflammatory Diseases in Childhood Balkan Med J 2020 37 5 236 246 32338845
Yıldız M, Haşlak F, Adrovic A, Barut K, Kasapçopur Ö (2020) Autoinflammatory Diseases in Childhood. Balkan Med J 37(5):236–24632338845
6. Padeh S Berkun Y Familial Mediterranean fever Curr Opin Rheumatol 2016 28 5 523 529 10.1097/BOR.0000000000000315 27286236
Padeh S, Berkun Y (2016) Familial Mediterranean fever. Curr Opin Rheumatol 28(5):523–52927286236
7. Yalçinkaya F A new set of criteria for the diagnosis of familial Mediterranean fever in childhood Rheumatology (Oxford) 2009 48 4 395 398 10.1093/rheumatology/ken509 19193696
Yalçinkaya F et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48(4):395–39819193696
8. Avar-Aydın PO The expanded spectrum of arthritis in children with familial Mediterranean fever Clin Rheumatol 2022 41 5 1535 1541 10.1007/s10067-022-06082-6 35091781
Avar-Aydın PO et al (2022) The expanded spectrum of arthritis in children with familial Mediterranean fever. Clin Rheumatol 41(5):1535–154135091781
9. Ozen S Update in familial Mediterranean fever Curr Opin Rheumatol 2021 33 5 398 402 10.1097/BOR.0000000000000821 34397603
Ozen S (2021) Update in familial Mediterranean fever. Curr Opin Rheumatol 33(5):398–40234397603
10. Sozeri B Kasapcopur O Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis Curr Med Chem 2015 22 16 1986 1991 10.2174/0929867322666150311152300 25760087
Sozeri B, Kasapcopur O (2015) Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis. Curr Med Chem 22(16):1986–199125760087
11. Salehzadeh F Mirzarahimi M Recurrent synovitis of hip and MEFV gene related arthritis in children Pediatr Rheumatol Online J 2020 18 1 63 10.1186/s12969-020-00456-3 32778116
Salehzadeh F, Mirzarahimi M (2020) Recurrent synovitis of hip and MEFV gene related arthritis in children. Pediatr Rheumatol Online J 18(1):6332778116
12. Ben-Chetrit E Touitou I Familial mediterranean Fever in the world Arthritis Rheum 2009 61 10 1447 1453 10.1002/art.24458 19790133
Ben-Chetrit E, Touitou I (2009) Familial mediterranean Fever in the world. Arthritis Rheum 61(10):1447–145319790133
13. Ozer E The frequency of juvenile spondyloarthropathies in childhood familial Mediterranean fever Clin Exp Rheumatol 2018 36 6 Suppl 115 141 145 30418123
Ozer E et al (2018) The frequency of juvenile spondyloarthropathies in childhood familial Mediterranean fever. Clin Exp Rheumatol 36(6 Suppl 115):141–14530418123
14. Petty RE International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 J Rheumatol 2004 31 2 390 392 14760812
Petty RE et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–39214760812
15. Özen S Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach Rheumatology (Oxford) 2021 60 8 3799 3808 10.1093/rheumatology/keaa863 33331943
Özen S et al (2021) Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology (Oxford) 60(8):3799–380833331943
16. Kallinich T Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement Pediatrics 2007 119 2 e474 e483 10.1542/peds.2006-1434 17242135
Kallinich T et al (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119(2):e474–e48317242135
17. Tufan A Lachmann HJ Familial mediterranean fever, from pathogenesis to treatment: a contemporary review Turk J Med Sci 2020 50 1591 1610 10.3906/sag-2008-11 32806879
Tufan A, Lachmann HJ (2020) Familial mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci 50:1591–161032806879
18. Demir F The musculoskeletal system manifestations in children with familial Mediterranean fever North Clin Istanb 2020 7 5 438 442 33163878
Demir F et al (2020) The musculoskeletal system manifestations in children with familial Mediterranean fever. North Clin Istanb 7(5):438–44233163878
19. Battal F The MEFV gene pathogenic variants and phenotype-genotype correlation in children with familial Mediterranean fever in the Çanakkale population Balkan J Med Genet 2016 19 2 23 28 10.1515/bjmg-2016-0032 28289585
Battal F et al (2016) The MEFV gene pathogenic variants and phenotype-genotype correlation in children with familial Mediterranean fever in the Çanakkale population. Balkan J Med Genet 19(2):23–2828289585
20. Öztürk K Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort Front Pediatr 2021 9 805919 10.3389/fped.2021.805919 35127599
Öztürk K et al (2021) Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort. Front Pediatr 9:80591935127599
21. Kilic A Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever Pediatr Rheumatol Online J 2015 13 59 10.1186/s12969-015-0057-1 26759267
Kilic A et al (2015) Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever. Pediatr Rheumatol Online J 13:5926759267
22. Güngörer V Yorulmaz A Arslan Ş The clinical effect of gene mutations in familial Mediterranean fever disease Pediatr Int 2022 64 1 e15052 10.1111/ped.15052 34743384
Güngörer V, Yorulmaz A, Arslan Ş (2022) The clinical effect of gene mutations in familial Mediterranean fever disease. Pediatr Int 64(1):e1505234743384
23. Ozturk K Cakan M The analysis of genotype-phenotype correlation in familial Mediterranean fever Pediatr Int 2022 64 1 e15017 10.1111/ped.15017 34606655
Ozturk K, Cakan M (2022) The analysis of genotype-phenotype correlation in familial Mediterranean fever. Pediatr Int 64(1):e1501734606655
24. Kunt S The effect of genotype on musculoskeletal complaints in patients with familial Mediterranean fever Postgrad Med 2020 132 2 220 224 10.1080/00325481.2019.1708147 31903829
Kunt S et al (2020) The effect of genotype on musculoskeletal complaints in patients with familial Mediterranean fever. Postgrad Med 132(2):220–22431903829
25. Jarjour RA Dodaki R Arthritis patterns in familial Mediterranean fever patients and association with M694V mutation Mol Biol Rep 2011 38 3 2033 2036 10.1007/s11033-010-0326-5 20845072
Jarjour RA, Dodaki R (2011) Arthritis patterns in familial Mediterranean fever patients and association with M694V mutation. Mol Biol Rep 38(3):2033–203620845072
26. Tunca M Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study Medicine (Baltimore) 2005 84 1 1 11 10.1097/01.md.0000152370.84628.0c 15643295
Tunca M et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1–1115643295
27. Yildiz M Evaluation of co-existing diseases in children with familial Mediterranean fever Rheumatol Int 2020 40 1 57 64 10.1007/s00296-019-04391-9 31352561
Yildiz M et al (2020) Evaluation of co-existing diseases in children with familial Mediterranean fever. Rheumatol Int 40(1):57–6431352561
28. Ayaz NA Comorbidities and phenotype-genotype correlation in children with familial Mediterranean fever Rheumatol Int 2021 41 1 113 120 10.1007/s00296-020-04592-7 32347339
Ayaz NA et al (2021) Comorbidities and phenotype-genotype correlation in children with familial Mediterranean fever. Rheumatol Int 41(1):113–12032347339
29. Beşer ÖF Association of familial Mediterranean fever in Turkish children with inflammatory bowel disease Turk Pediatri Ars 2014 49 3 198 202 10.5152/tpa.2014.1998 26078663
Beşer ÖF et al (2014) Association of familial Mediterranean fever in Turkish children with inflammatory bowel disease. Turk Pediatri Ars 49(3):198–20226078663
30. Konte EK Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience Eur J Pediatr 2023 182 12 5473 5482 10.1007/s00431-023-05209-4 37777601
Konte EK et al (2023) Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience. Eur J Pediatr 182(12):5473–548237777601
31. Balcı-Peynircioğlu B Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients Rheumatology (Oxford) 2020 59 6 1372 1380 10.1093/rheumatology/kez410 31598713
Balcı-Peynircioğlu B et al (2020) Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients. Rheumatology (Oxford) 59(6):1372–138031598713
32. Amaryan G Khloyan G Sarkisian T Tadevosyan A Saurenmann RK Joint manifestations in children with familial mediterranean fever in Armenia: clinical and genetic characteristics Int J Immunol 2021 9 2 22 28 10.11648/j.iji.20210902.11
Amaryan G, Khloyan G, Sarkisian T, Tadevosyan A, Saurenmann RK (2021) Joint manifestations in children with familial mediterranean fever in Armenia: clinical and genetic characteristics. Int J Immunol 9(2):22–28
33. Sahin S Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER Pediatr Rheumatol Online J 2021 19 1 134 10.1186/s12969-021-00613-2 34425847
Sahin S et al (2021) Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER. Pediatr Rheumatol Online J 19(1):13434425847
34. Kaşifoğlu T The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis Clin Rheumatol 2009 28 1 41 46 10.1007/s10067-008-0980-3 18795391
Kaşifoğlu T et al (2009) The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 28(1):41–4618795391
35. Akar S High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection Arthritis Res Ther 2013 15 1 R21 10.1186/ar4154 23356447
Akar S et al (2013) High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection. Arthritis Res Ther 15(1):R2123356447
36. Lidar M Incomplete response to colchicine in M694V homozygote FMF patients Autoimmun Rev 2012 12 1 72 76 10.1016/j.autrev.2012.07.025 22884555
Lidar M et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12(1):72–7622884555
37. Kisaoglu H Baba O Kalyoncu M Genotype-Phenotype Associations of Children With Familial Mediterranean Fever in a Cohort Consisting of M694V Mutation and Implications for Colchicine-Resistant Disease J Clin Rheumatol 2023 29 4 207 213 36870084
Kisaoglu H, Baba O, Kalyoncu M (2023) Genotype-Phenotype Associations of Children With Familial Mediterranean Fever in a Cohort Consisting of M694V Mutation and Implications for Colchicine-Resistant Disease. J Clin Rheumatol 29(4):207–21336870084
38. Ayla A, Yenigun S, Baspinar SN, Yuzbasioglu MB, Alkan A, Durucan I, Kirman M, Polat BC, Ergun S, Ugurlu S, Ozdogan H (2022) Characteristics of arthritis in familial Mediterranean fever patients [Abstract]. In: Arthritis & Rheumatology, ACR. Philadelphia.
39. Ozen S EULAR recommendations for the management of familial Mediterranean fever Ann Rheum Dis 2016 75 4 644 651 10.1136/annrheumdis-2015-208690 26802180
Ozen S et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–65126802180
